| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study LB Saltz, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... Journal of clinical oncology 26 (12), 2013-2019, 2008 | 3998 | 2008 |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3679 | 2016 |
| Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous … JB Vermorken, J Trigo, R Hitt, P Koralewski, E Diaz-Rubio, F Rolland, ... Journal of clinical oncology 25 (16), 2171-2177, 2007 | 1163 | 2007 |
| Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... Journal of clinical oncology 26 (12), 2006-2012, 2008 | 1129 | 2008 |
| Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ... The lancet oncology 15 (4), 406-414, 2014 | 974 | 2014 |
| XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer J Cassidy, J Tabernero, C Twelves, R Brunet, C Butts, T Conroy, ... Journal of Clinical Oncology 22 (11), 2084-2091, 2004 | 743 | 2004 |
| Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the … J Franko, Q Shi, JP Meyers, TS Maughan, RA Adams, MT Seymour, ... The Lancet Oncology 17 (12), 1709-1719, 2016 | 576 | 2016 |
| Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines D Machover, E Diaz-Rubio, A De Gramont, A Schilf, JJ Gastiaburu, ... Annals of Oncology 7 (1), 95-98, 1996 | 499 | 1996 |
| Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Tabernero, E Van Cutsem, E Díaz-Rubio, A Cervantes, Y Humblet, ... Journal of clinical oncology 25 (33), 5225-5232, 2007 | 405 | 2007 |
| Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final … E Díaz-Rubio, J Tabernero, A Gómez-España, B Massutí, J Sastre, ... Journal of Clinical Oncology 25 (27), 4224-4230, 2007 | 364 | 2007 |
| XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... British journal of cancer 105 (1), 58-64, 2011 | 328 | 2011 |
| Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study E Diaz-Rubio, J Sastre, A Zaniboni, R Labianca, H Cortes-Funes, ... Annals of Oncology 9 (1), 105-108, 1998 | 311 | 1998 |
| Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables J Sastre, ML Maestro, J Puente, S Veganzones, R Alfonso, S Rafael, ... Annals of Oncology 19 (5), 935-938, 2008 | 303 | 2008 |
| Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis FC Bidard, S Michiels, S Riethdorf, V Mueller, LJ Esserman, A Lucci, ... JNCI: Journal of the National Cancer Institute 110 (6), 560-567, 2018 | 290 | 2018 |
| First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase … E Díaz-Rubio, A Gómez-España, B Massutí, J Sastre, A Abad, ... The oncologist 17 (1), 15-25, 2012 | 282 | 2012 |
| The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper M Cristofanilli, JY Pierga, J Reuben, A Rademaker, AA Davis, DJ Peeters, ... Critical reviews in oncology/hematology 134, 39-45, 2019 | 271 | 2019 |
| Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF … M Martin, A Villar, A Sole-Calvo, R Gonzalez, B Massuti, J Lizon, ... Annals of Oncology 14 (6), 833-842, 2003 | 261 | 2003 |
| Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence … C Twelves, W Scheithauer, J McKendrick, JF Seitz, G Van Hazel, A Wong, ... Annals of oncology 23 (5), 1190-1197, 2012 | 242 | 2012 |
| Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials HT Arkenau, D Arnold, J Cassidy, E Diaz-Rubio, JY Douillard, H Hochster, ... Journal of Clinical Oncology 26 (36), 5910-5917, 2008 | 234 | 2008 |
| Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium J Bellmunt, V Guillem, L Paz-Ares, JL Gonzalez-Larriba, J Carles, ... Journal of clinical oncology 18 (18), 3247-3255, 2000 | 228 | 2000 |
